Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|膽管癌症治療的全球市場:2020年∼2027年 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market - 2020-2027|
|出版日期: 2021年05月12日||內容資訊: 英文 180 Pages||
The Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Bile Duct Cancer, also known as Cholangiocarcinoma, forms in the slender tubes (bile ducts) that carry the digestive fluid bile. Bile ducts connect the liver to the gallbladder and small intestine. It occurs mainly in people older than age 50, though it can occur at any age. The particular causes of bile duct cancer are unknown. However, few factors responsible for developing bile duct cancer are long-term inflammation in the liver, biliary stones, abnormalities in the bile duct such as cysts, infection with liver fluke's parasite that causes mainly infection in the bile duct leading to cancer, and exposure to harmful chemicals and toxins. Major symptoms associated with bile duct cancer include jaundice, weight loss, loss of appetite, discoloration of urine and stool, abdominal pain, itching, and fever. Bile duct cancer is treated by Chemotherapy, Surgery, Radiation therapy, Targeted therapy and Others.
The global Bile Duct Cancer (Cholangiocarcinoma) Treatment growth is driven by the increasing prevalence of bile duct cancers worldwide, increasing geriatric population, changing lifestyle and increasing smoking habits; rising investment in research and development activities are the major factors driving the market.
The increasing prevalence of bile duct cancers worldwide is expected to drive the growth in the forecast period.
Bile duct cancer (Cholangiocarcinoma) is rare. As per the National Cancer Institute, the rate of new cases of bile duct cancer was 9.0 per 100,000 men and women per year. In 2018, an estimated 96,178 people were living with bile duct cancer in the United States. In 2021, it is estimated that there will be 42,230 new cases of bile duct cancer are estimated. This includes intrahepatic (inside the liver) and extrahepatic (outside the liver) bile duct cancers, but the actual number of cases is likely to be higher because these cancers can be hard to diagnose, and some might be misclassified as other types of cancer. These factors are majorly driving the growth of the market.
High treatment costs are likely to hinder market growth.
According to the American cancer clinical society, approximate bile duct Cancer Treatment cost in India ranges between USD 1500 to USD 15,000. It is a burden for underdeveloped and developing countries. This is one of the factors hampering the market growth.
COVID-19 Impact Analysis
The COVID-19 pandemic has negatively impacted healthcare systems globally and on the vulvar Cancer market. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the Ongoing clinical trials too. However, the situation is expected to improve gradually.
Based on the Cancer Type, the global Bile Duct Cancer (Cholangiocarcinoma) Treatment market is segmented into Intrahepatic bile duct cancer and Extrahepatic bile duct cancer.
Intrahepatic bile duct cancer
Intrahepatic bile duct cancer occurs in the bile ducts within the liver and is sometimes classified as a type of liver cancer. This type makes up 5% to 10% of cases.
Extrahepatic bile duct cancer: This type occurs more often and is more treatable might form in one of two areas.
The hilum region, where your left and right bile ducts come together to form the common hepatic duct. It is called perihilar cancer. More than 60% of the plethora of bile duct cancers fall in the category of perihilar bile duct cancers.
The distal Region, where your common bile duct passes through the pancreas. This is called distal cancer.
Based on the Treatment Type, the global Bile Duct Cancer (Cholangiocarcinoma) Treatment market is segmented into Chemotherapy, Surgery, Radiation therapy, Photodynamic therapy, and Others.
The chemotherapy segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)
Chemotherapy (chemo) is treatment with cancer-killing drugs usually given into a vein (IV) or taken by mouth. These drugs enter the bloodstream and reach all areas of the body, making this helpful treatment for some cancers that have spread to organs beyond the bile duct. As the drugs reach all the areas of the body, this is known as a systemic treatment. The drugs used in chemo are 5-fluorouracil, gemcitabine, capecitabine, oxaliplatin, cisplatin, and combined drug treatment. Factors such as the availability of a wide range of chemotherapeutics agents for the treatment of bile duct cancer and ongoing innovative research work on the improvement of chemotherapy by studying new drugs and new combination of drugs through clinical trials are anticipated to boost the market growth of the chemotherapy segment during the forecast period.
For instance, Incyte Corporation- A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants with Unresectable or Metastatic Cholangiocarcinoma.
Based on End-User, the global Bile Duct Cancer (Cholangiocarcinoma) Treatment market is segmented into Hospitals, Cancer Research centers, clinics, others.
Due to the growing patient population, the hospital segment held the largest market share. This is mainly due to the increasing number of patients suffering from conditions treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals and adequate reimbursement policies are also contributing to the growth of this segment. Also, the medications can be administrated intravenously, and surgery is done under the supervision of medical practitioners at these locations.
Bile Duct Cancer, also known as Cholangiocarcinoma, is spreading widely in Southeast Asia. The high consumption of raw fish in the Asia-Pacific (APAC) region drives the incidence of liver fluke infections, thereby stimulating bile duct cancer. Increased industrialization is also attributing to the growth in the APAC region as exposure to harmful printing chemicals is high among industrial workers in countries such as China, Japan and India. For instance, Eisai Co., Ltd- A Phase 2 Trial of E7090 in Subjects With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion.
North America holds the second-largest market in the global bile duct cancer market due to the high incidence of cancer, according to the International Agency for Research on Cancer (IARC), which claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and photodynamic therapy methods, the total availability of advanced technological tools, FDA approval of new drugs and also the presence of a vast number of organizations engaged in R&D activities related to cancer vaccines.
The Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market is quite competitive with some key competitors like ConMed Corporation, Bristol-Myers Squibb, Johnson & Johnson, Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Incyte Corporation, Celgene Corp, Bayer AG, and Boston Scientific Corporation. The major players adopt several growth strategies such as product launches, acquisitions, and collaborations, contributing to the market's growth globally. For instance, Incyte Corporation-A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants with Unresectable or Metastatic Cholangiocarcinoma.
Hoffmann-La Roche Ltd
Company Overview: Roche was founded in 1896 in Basel, Switzerland. It creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to drive personalized healthcare further. Two-thirds of our Research and Development projects are being developed with companion diagnostics. Genentech becomes a member of the Roche Group in March of 2009.
Product Portfolio: The company portfolio includes Oncology, Neurology, Endocrinology, Infectious diseases and others.
Diagnostic Test: FoundationOne®CDx and FoundationOne®Liquid are under trials.
The global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market report would provide access to an approx. 61 market data table, 55 figures and 240 pages.
LIST NOT EXHAUSTIVE